Company intelligence / Profile preview
Aldea Pharmaceuticals
Redwood City, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
- The lead program AD-6626 is being evaluated in Phase 1 clinical trials to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy for acute alcohol toxicity in volunteers with wild type or heterozygous ALDH2 genetic variants[3].
- Intravenous and oral administration are under assessment[3].
- Preclinical research suggests potential utility enhancing ALDH1A1 activity, with implications for Fanconi anemia[3].
- Therapeutic areas
- PsychiatryHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Aldea Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aldea Pharmaceuticals.